CurrentEndo — Diabetes technology

Differences in the Glucose Management Indicator Between Continuous Glucose Monitoring Systems

2026-11-13T19:45:41.967Z

Cohort study · Diabetes Obes Metab, 2026.

Development and Validation of a Meal Detection-Based Tool for User Behavior and Meal Management Analysis

2026-11-13T18:46:09.627Z

Diagnostic or prognostic study · J Diabetes Sci Technol, 2026.

Improved glycemic control and lifestyle behaviors with Dexcom continuous glucose monitoring: one-year real-world outcomes from a global registry of people with non-insulin-treated type 2 diabetes in primary care

2026-11-13T17:00:16.153Z

Randomized controlled trial · Diabetes Res Clin Pract, 2026.

‘You've got something to look at and something to achieve’ : Perspectives of adults with type 2 diabetes on professional‐mode glucose monitoring. A GP ‐ OSMOTIC nested qualitative study

2026-11-13T17:00:16.153Z

Research article · Diabet Med, 2026.

Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial

2026-11-13T11:02:00.546Z

Randomized controlled trial · Nat Med, 2023. TIR 3.9-10.0 mmol/l: Closed-loop mean 66.3% ± 14.9% · Control mean 32.3% ± 24.7%

Association of Achieving Time in Range Clinical Targets With Treatment Modality Among Youths With Type 1 Diabetes

2026-11-13T11:00:06.281Z

Cohort study · JAMA Netw Open, 2023. TIR >70% target achieved (adjusted): rtCGM + pump 36.2% (95% CI 33.9%-38.4%) · rtCGM + injections 20.9% (95% CI 18.0%-24.1%) · isCGM + injections 12.5% (95% CI 10.7%-14.4%) · isCGM + pump 11.3% (95% CI 9.2%-13.8%)

Validation of a Hypoglycemia Risk Stratification Tool Using Data From Continuous Glucose Monitors

2026-11-13T11:00:06.281Z

Cohort study · JAMA Netw Open, 2023. Validation of a hypoglycemia risk stratification tool using CGM data

Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes

2026-11-13T10:58:35.797Z

Randomized controlled trial · N Engl J Med, 2023. Time in range 70 to 180 mg/dL, 13-week follow-up: Closed-loop mean 69.3 ± 11.1 % · Standard care mean 55.9 ± 12.6 %

Comparisons of School-Day Glycemia in Different Settings for Children with Type 1 Diabetes Using Continuous Glucose Monitoring

2026-11-13T10:46:56.512Z

Cohort study · Pediatr Diabetes, 2023. TIR, time above range (TAR), mean glucose and SD — Weekends vs In-school; p<0.001; TIR higher; TAR, mean glucose and SD lower with weekends and virtual school

Situational Awareness and Proactive Engagement Predict Higher Time in Range in Adolescents and Young Adults Using Hybrid Closed-Loop

2026-11-13T10:46:56.512Z

Cohort study · Pediatr Diabetes, 2023. Predictors of daily TIR (multivariable modeling): Underestimated glucose levels: lower TIR r = -0.22

Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring

2026-11-13T10:44:19.723Z

Randomized controlled trial · J Diabetes Sci Technol, 2023. Mean change in HbA1c from baseline, six months: AHCL mean decrease 1.70 percentage points · MDI + RT-CGM mean decrease 0.60 percentage points

Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review

2026-11-13T10:44:19.723Z

Meta-analysis · J Diabetes Sci Technol, 2022. Publications identified 387

Clinical Accuracy of a Glucose Oxidase–Based Blood Glucose Test-Strip Across Extremes of Oxygen Partial Pressure

2026-11-13T10:44:19.723Z

Diagnostic or prognostic study · J Diabetes Sci Technol, 2023. BGM bias by pressure of oxygen (Po2) (linear regression): Bias range across Po2 (low Po2 45 mm Hg to high Po2 105 mm Hg) 5.22% (+0.72% to -4.5%)

Continuous Glucose Monitoring of Steroid-Induced Hyperglycemia in Patients With Dermatologic Diseases

2026-11-13T10:44:19.723Z

Cohort study · J Diabetes Sci Technol, 2023. SIH incidence: Normoglycemia 2 · Prediabetes 4 · Diabetes 9

Costs and Outcomes Comparison of Diabetes Technology Usage Among People With Type 1 or 2 Diabetes Using Rapid-Acting Insulin

2026-11-13T10:44:19.723Z

Cohort study · J Diabetes Sci Technol, 2021. Adjusted first-year medical utilization and costs, first year: Only two comparisons statistically significant: pump had greater adjusted first-year total medical and office visit costs vs BGM

Design of a Real-Time Physical Activity Detection and Classification Framework for Individuals With Type 1 Diabetes

2026-11-13T10:44:19.723Z

Diagnostic or prognostic study · J Diabetes Sci Technol, 2023. Exercise onset predicted within 1 minute, average accuracy 81%

Effects of Alternate Insulin Pump Settings in Patients With Type 1 Diabetes During Ramadan: A Randomized Pilot Study

2026-11-13T10:44:19.723Z

Randomized controlled trial · J Diabetes Sci Technol, 2021. Time in target range (70-180 mg/dL): TIR increased significantly in the intervention group, from 63.0 ± 10.7 to 76 ± 16.2% (MD 27% points; P < .001)

Effects of Simulated Adverse Environmental Conditions Related to Actual Conditions at Health Promoting Hospitals on the Performance of Blood Glucose Testing by Glucose Meters

2026-11-13T10:44:19.723Z

Mechanistic study · J Diabetes Sci Technol, 2021. Median-paired differences of glucose measurements, stressed vs unstressed test strips, short term (3 days) and long term (30 days) — Stressed test strips vs Unstressed test strips: median-paired differences; P < 0.05; significant differences at 5 simulated conditions with 4 glucose meters

Estimation of a Machine Learning-Based Decision Rule to Reduce Hypoglycemia Among Older Adults With Type 1 Diabetes: A Post Hoc Analysis of Continuous Glucose Monitoring in the WISDM Study

2026-11-13T10:44:19.723Z

Secondary analysis · J Diabetes Sci Technol, 2023. Optimal decision rule assigning CGM vs BGM to minimise % time <70 mg/dL, all follow-up visits: Optimal decision rule: decision list with 3 steps

Evaluation of a Continuous Blood Glucose Monitor: A Novel and Non-Invasive Wearable Using Bioimpedance Technology

2026-11-13T10:44:19.723Z

Cohort study · J Diabetes Sci Technol, 2021. Accuracy of model-estimated BGL from bioimpedance data (gradient boosted model, 80-20 training-test split): MARD of estimated BGL 17.9%

Hybrid Closed Loop Using a Do-It-Yourself Artificial Pancreas System in Adults With Type 1 Diabetes

2026-11-13T10:44:19.723Z

Randomized controlled trial · J Diabetes Sci Technol, 2023. TIR (70-180 mg/dL), final week of each four-week arm: AAPS 76.6% ± 11.7% · Stand-alone pump 58.0% ± 15.6%

Impact of Infusion Set Materials and Designs on the Subcutaneous Response in People With Diabetes: A Rapid Review of the Literature

2026-11-13T10:44:19.723Z

Research article · J Diabetes Sci Technol, 2022. Subcutaneous tissue response to IIS materials: No substantial difference in tissue response to steel vs Teflon cannulas suggested

Improved Glycemic Control Using a Bluetooth®-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144 000 People With Diabetes

2026-11-13T10:44:19.723Z

Cohort study · J Diabetes Sci Technol, 2023. RIR change from baseline, 180 days: PwT1D +6.1 percentage points; baseline 54.5%; 180 days 60.6% · PwT2D +11.9 percentage points; baseline 68.2%; 180 days 80.1%

Interruption of Continuous Glucose Monitoring: Frequency and Adverse Consequences

2026-11-13T10:44:19.723Z

Cross-sectional study · J Diabetes Sci Technol, 2023. CGM disruption events: Device malfunction 85.4%

Multicenter Evaluation Study Comparing a New Factory-Calibrated Real-Time Continuous Glucose Monitoring System to Existing Flash Glucose Monitoring System

2026-11-13T10:44:19.723Z

Diagnostic or prognostic study · J Diabetes Sci Technol, 2021. Accurate readings vs venous blood glucose (continuous glucose error grid analysis (CG-EGA)): AiDEX 98.69% · Abbott Libre 98.96%

Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes

2026-11-13T10:44:19.723Z

Research article · J Diabetes Sci Technol, 2023. Accuracy vs comparator: MARD and relative bias, 28-day study period: FBS 14.7%; relative bias -2.1%; sensor-to-sensor variability low · FL2 9.2%; relative bias -2.5%; sensor-to-sensor variability moderate · ADX 21.9%; relative bias -18.5%; sensor-to-sensor variability high

Post-Market Surveillance Assessment of the Clinical Accuracy of a Blood Glucose Monitoring System with an Improved Algorithm for Enhanced Product Performance

2026-11-13T10:44:19.723Z

Diagnostic or prognostic study · J Diabetes Sci Technol, 2021. Clinical accuracy vs comparator: FDA: values within ±15% of comparator 98.9%

Post-Market Surveillance of a Blood Glucose Test Strip Demonstrates No Evidence of Interference on Clinical Accuracy in a Large Cohort of People with Type 1 or Type 2 Diabetes

2026-11-13T10:44:19.723Z

Diagnostic or prognostic study · J Diabetes Sci Technol, 2021. Readings meeting EN ISO 15197:2015 clinical accuracy criteria, by number of individual medications: 1-3 97.7% · 4-6 97.7% · 7-9 97.8% · 10-12 97.8% · >12 98.4%

Reliability of Inpatient CGM: Comparison to Standard of Care

2026-11-13T10:44:19.723Z

Research article · J Diabetes Sci Technol, 2021. Mean absolute relative difference, CGM vs POC BG: BBT mean 24.6% ± 8.1; median 23.4% · IVI mean 19.6% ± 9.4; median 16.0%

Updated Psychosocial Surveys With Continuous Glucose Monitoring Items for Youth With Type 1 Diabetes and Their Caregivers

2026-11-13T10:44:19.723Z

Diagnostic or prognostic study · J Diabetes Sci Technol, 2023. Internal consistency of updated surveys (Cronbach α): DFC youth α .91

Use of Continuous Glucose Monitoring in Non-ICU Hospital Settings for People With Diabetes: A Scoping Review of Emerging Benefits and Issues

2026-11-13T10:44:19.723Z

Research article · J Diabetes Sci Technol, 2021. Benefits and issues of continuous glucose monitoring (CGM) and flash glucose monitoring (FGM) on general wards: CGM and FGM on general wards could lead to improved glycemic control, decreased LOS, and reduced risk of severe hypoglycemia or hyperglycemia

Vacuum-Assisted Needle-Free Capillary Blood Sampling

2026-11-13T10:44:19.723Z

Research article · J Diabetes Sci Technol, 2023. Glucose concentration in blood collected under vacuum after jet injection and lancing was equivalent

Variation in the Current Use of Technology to Support Diabetes Management in UK Hospitals: Results of a Survey of Health Care Professionals

2026-11-13T10:44:19.723Z

Cross-sectional study · J Diabetes Sci Technol, 2023. Use of technology to support inpatient diabetes care: Significant variation between organizations in the use of technology to support safe, effective inpatient diabetes care

A Comparison of Continuous Glucose Monitoring Estimated Hemoglobin A1c in Adults with Type 1 or Type 2 Diabetes

2026-11-13T10:42:28.137Z

Meta-analysis · Diabetes Technol Ther, 2022. CGM mean glucose–HbA1c relationship — T2D vs T1D; P = 0.002; HbA1c on average higher with T2D than T1D for the same mean glucose

A Longitudinal View of Disparities in Insulin Pump Use Among Youth with Type 1 Diabetes: The SEARCH for Diabetes in Youth Study

2026-11-13T10:42:28.137Z

Cross-sectional study · Diabetes Technol Ther, 2022. Hispanic vs White: OR 0.57 (95% CI 0.45-0.73)

A New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes

2026-11-13T10:42:28.137Z

Diagnostic or prognostic study · Diabetes Technol Ther, 2023. SISP estimation precision and correlation with SIMM: Real 100%; meals with good precision (median CV <20%) 100%; R (SISP vs SIMM) 0.83 · Simulated 91%; meals with good precision (median CV <20%) 91%; R (SISP vs SIMM) 0.82

A Statistical Approach for Assessing the Compliance of Integrated Continuous Glucose Monitoring Systems with Food and Drug Administration Accuracy Requirements

2026-11-13T10:42:28.137Z

Research article · Diabetes Technol Ther, 2023. CI estimation of agreement rates (ARs): A bootstrap-based method that accounts for the clustered structure of CGM data is reliable and robust

An Assessment of Clinical Continuous Glucose Monitoring Targets for Older and High-Risk People Living with Type 1 Diabetes

2026-11-13T10:42:28.137Z

Secondary analysis · Diabetes Technol Ther, 2022. Correlations of CGM metrics, baseline: TIR vs TAR (strong) r = -0.966; P < 0.0001

Assessment of the Glucose Management Indicator Using Different Sampling Durations

2026-11-13T10:42:28.137Z

Secondary analysis · Diabetes Technol Ther, 2022. Agreement of shorter-duration GMI with 14-day GMI: 10-day GMI: correlation with 14-day GMI 0.98; GMI values within 0.3% of 14-day GMI 98% · 7-day GMI: correlation with 14-day GMI 0.95; GMI values within 0.3% of 14-day GMI 87% · 5-day GMI: correlation with 14-day GMI 0.91; GMI values within 0.3% of 14-day GMI 77% · 3-day GMI: correlation with 14-day GMI 0.86; GMI values within 0.3% of 14-day GMI 60%

Attitudes and Behaviors with Diabetes Technology Use in the Hospital: Multicenter Survey Study in the United States

2026-11-13T10:42:28.137Z

Cross-sectional study · Diabetes Technol Ther, 2022. Attitudes, behaviors and barriers with continuous subcutaneous insulin infusion (CSII) and continuous glucose monitor (CGM) use in hospital: Rated treatment of inpatient hyperglycemia important 96%

Composite Metric of Glycemic Control Q-Score Is Elevated in Pediatric and Adolescent/Young Adult Hematopoietic Stem Cell Transplant Recipients

2026-11-13T10:42:28.137Z

Cohort study · Diabetes Technol Ther, 2022. Q-score, peri-HSCT period: Median Q-score (IQR 8.3, 14.3) 10.2

Discordance Between Glucose Management Indicator and Glycated Hemoglobin in People Without Diabetes

2026-11-13T10:42:28.137Z

Cohort study · Diabetes Technol Ther, 2023. Discordance between GMI and HbA1c: Mean GMI higher than laboratory HbA1c 0.59%

Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring

2026-11-13T10:42:28.137Z

Research article · Diabetes Technol Ther, 2022. TIR 70-180 mg/dL, 6 months: Baseline 65.3% · AHCL 6 months 73.8%

Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study

2026-11-13T10:42:28.137Z

Cohort study · Diabetes Technol Ther, 2023. CGM-derived glucose metrics (baseline vs first month): %TIR 70-180 mg/dL 54.86 ± 17 vs. 72.23 ± 10.11

Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial

2026-11-13T10:42:28.137Z

Randomized controlled trial · Diabetes Technol Ther, 2023. time in range (TIR) 3.9-10 mmol/L (70-180 mg/dL), 52 weeks of data: AID 69.1% (CI 67.1 to 71.1) · SAPT 56.9% (CI 54.2 to 59.6)

Frequency and Detection of Insulin Infusion Site Failure in the Type 1 Diabetes Exchange Online Community

2026-11-13T10:42:28.137Z

Cross-sectional study · Diabetes Technol Ther, 2023. IIS failure ≥1 per month: Reported ≥1 IIS failure per month 41.4%

Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery

2026-11-13T10:42:28.137Z

Secondary analysis · Diabetes Technol Ther, 2022. % time in target range 5.6-10.0 mmol/L, over the time of hospitalization: FCL mean 77.7% ± 4.6% % time · UC mean 41.1% ± 19.5% % time

Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial

2026-11-13T10:42:28.137Z

Research article · Diabetes Technol Ther, 2023. Plasma glucose time below range (TBR) (<3.9 mmol/L), time in range (TIR) (3.9-10.0 mmol/L), time above range (TAR) (>10.0 mmol/L) around exercise, 3-h monitoring period — UP vs AID; P = 0.413; TBR: UP 11 ± 21 vs AID 3% ± 10%

Improving Continuous Glucose Monitoring Uptake in Underserved Youth with Type 1 Diabetes: The IMPACT Study

2026-11-13T10:42:28.137Z

Research article · Diabetes Technol Ther, 2022. Uptake of personal CGM, 3-6 months follow-up: Wanted personal CGM after trial CGM use 85%

Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes

2026-11-13T10:42:28.137Z

Research article · Diabetes Technol Ther, 2023. Change in CGM use after policy change: Immediate change in CGM use, T1D 9.5% (P < 0.0001)